Status:
UNKNOWN
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Lead Sponsor:
Hamamatsu University
Conditions:
Helicobacter Infections
Gastritis
Eligibility:
All Genders
20-90 years
Phase:
PHASE2
PHASE3
Brief Summary
Proton pump inhibitors (PPIs) are mainly metabolized in the liver by CYP2C19, one of the cytochrome P450 isoenzymes, which shows a genetic polymorphism associated with enzyme activities. The most esse...
Eligibility Criteria
Inclusion
- Patients with H. pylori infection
Exclusion
- Patients without H. pylori infection
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00197418
Start Date
August 1 2003
Last Update
March 21 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192